Order Article Reprints

Altıntaş YE, Kınıkoğlu O, Işık D, Batu A, Bayramgil A, Niğdelioğlu B, Özkerim U, Öksüz S, Sürmeli H, Turan N, et al. Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy. Current Oncology. 2025; 32(9):503. https://doi.org/10.3390/curroncol32090503

Altıntaş, Yunus Emre, Oğuzcan Kınıkoğlu, Deniz Işık, Aziz Batu, Ayberk Bayramgil, Büşra Niğdelioğlu, Uğur Özkerim, Sıla Öksüz, Heves Sürmeli, Nedim Turan, and et al. 2025. "Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy" Current Oncology 32, no. 9: 503. https://doi.org/10.3390/curroncol32090503

Altıntaş, Y. E., Kınıkoğlu, O., Işık, D., Batu, A., Bayramgil, A., Niğdelioğlu, B., Özkerim, U., Öksüz, S., Sürmeli, H., Turan, N., & Odabaş, H. (2025). Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy. Current Oncology, 32(9), 503. https://doi.org/10.3390/curroncol32090503